Reduction of C-reactive protein levels through use of a multivitamin - 28/08/11
Abstract |
Purpose |
Elevated C-reactive protein levels are associated with the risk of cardiovascular disease and diabetes. We examined whether multivitamins reduce C-reactive protein levels.
Methods |
We performed a post hoc subgroup analysis of a 6-month, randomized, double-blind, placebo-controlled trial. Patients (n = 87; mean age, 53 years) for whom frozen plasma samples were available; who did not have an inflammatory condition at baseline; and who were not hospitalized, taking antibiotics, smoking, or starting statin therapy during the study were included. C-reactive protein and plasma vitamin levels were measured at baseline and 6 months.
Results |
At 6 months, C-reactive protein levels were significantly lower in the multivitamin group than in the placebo group (between-group difference = –0.91 mg/L; 95% confidence interval: –1.52 to –0.30; P= 0.005). The reduction in C-reactive protein levels was most evident in patients who had elevated levels (≥1.0 mg/L) at baseline. Of the six vitamins measured (C, E, B6, B12, folate, and beta carotene), only vitamin B6 (baseline: r = –0.31, P= 0.003; 6 months: r = –0.29, P= 0.006) and vitamin C (baseline: r = –0.25, P= 0.02) were inversely associated with C-reactive protein level.
Conclusion |
In a post hoc analysis of a randomized, double-blind, placebo-controlled study, multivitamin use was associated with lower C-reactive protein levels. Other similarly formulated multivitamins may yield comparable results.
Le texte complet de cet article est disponible en PDF.Plan
This study was supported in part by the Simmons Foundation, Cooper Concepts, and private contributions. |
Vol 115 - N° 9
P. 702-707 - décembre 2003 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?